NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting
(Thomson Reuters ONE) -
NANOBIOTIX: PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH
NBTXR3
PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING
* Very good safety profile with no AEs and SAEs in stage III/IV in frail
patients older than 70 years old
* 7 out 9 patients had Complete Reponse at 10% dose level or more
* Follow up shows a potential impact on long term disease control
* Amendment filed for a dose expansion cohort of 44 additional patients
* Plan to open this study in the United States
Paris, France and Cambridge, Massachusetts, June 5, 2017 - NANOBIOTIX (Euronext:
NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company
pioneering new approaches to the treatment of cancer, presented the results of
the Phase I/II head and neck cancer trial with its lead product candidate,
NBTXR3, at the American Society of Clinical Oncology (ASCO), Chicago.
Nanobiotix's Chief Medical Officer Elsa Borghi said: "The very good level of
tolerance seen so far, the absence of Adverse Events related to the product, and
the rate of Complete Response in this population, indicates that NBTRX3 could
play a key role in the treatment of head and neck cancer. It could potentially
have a direct impact on the patients' outcome via Loco-regional Control, Quality
of Life, Safety and Overall Survival."
Illustration : 3D reconstruction of CT scan (tumor in yellow) patient treated at
a 15% dose level showing a Complete Response 7 months after the end of the
treatment.
Population treated
Head and neck cancers represent a group of aggressive cancers that appear in the
mouth, nose, sinuses and at the top of the aerodigestive tract. This disease is
a major public health concern in USA, Europe and Asia.
Nanobiotix's Phase I/II head and neck trial targets frail and elderly patients
(more than 70 years) who have advanced stage III/IV cancer with very limited
therapeutic options. The only available treatment for these patients is
radiotherapy, as their condition does not allow them to receive a combination of
radiotherapy and chemotherapy, which offers a better survival outcome. These
patients with radiotherapy treatment alone have a poorer outcome with lower
Response Rate, and shorter Overall Survival. Uncontrolled tumor growth in such
population will significantly decrease patients' Quality of Life because basic
functions such as swallowing, breathing, speaking and eating are impaired.
The use of Nanobiotix's NBTXR3 in this population aims to provide better local
and systemic desease control and prolongs survival with the improvement of
Quality of Life.
Results presented at ASCO annual meeting (Abstract #6080)
A phase I trial of NBTXR3 nanoparticles activated by intensity-modulated
radiation therapy (IMRT) in the treatment of advanced-stage head and neck
squamous cell carcinoma (HNSCC). (Poster board #68, Authors: Christophe Le
Tourneau, MD, PhD, Valentin Calugaru, Thomas Jouffroy, Jose Rodriguez, Caroline
Hoffmann, Bernard Dodger, Victor Moreno, Emiliano Calvo; Institut Curie, Paris,
France; START Madrid, FJD, Madrid, Spain; Centro Integral Oncológico Clara
Campal, Madrid, Spain).
1. Primary endpoints: Safety and Feasibility
NBTXR3 has demonstrated an excellent safety profile, with no Adverse Events
(serious or not) related to the product.The radiotherapy safety observed in the
trial has been strictly the same to the IMRT well-known toxicity. This is an
important finding, given the elderly and frail population treated in this trial.
Additionally, the injection was demonstrated to be feasible and appropriate as
the product remained in the tumor from the first day until the last day of
radiotherapy. Marginal passage in the blood circulation has been observed during
injection time. No leakage in the surrounding tissues have been observed. The
highest dose (22%) continues to be evaluated.
2. Exploratory endpoints: efficacy and patient outcome (follow up and duration
of Response)
The Overall Response Rate (Partial Response plus Complete Response) was
evaluated as per RECIST 1.1.
The first data showed promising signs of antitumor activity. The Overall
Response Rate is 91% (10 out of 11 patients evaluable) and 7 out 9 patients
(78%) had Complete Reponse at 10% dose level or more. In addition, the tumor
response suggests a dose dependent effect (see figure below: waterfall plot).
So far, all of the patients treated at higher dose levels (15% and 22%) have
shown a prolongated Response with no loco-regional or distant relapse, with a
medium follow up of 12 months.
Best Response obtained for patients at different dose levels (*patient one non
evaluable)
Additional findings
The trial also showed that most of the Complete Responses occurred between 3 and
10 months after the end of the treatment, during the follow-up period when
patients were not receiving any oncology treatments. Interestingly late
appearance of tumor Complete Response as well as an unusual case of Pseudo
Disease Progression followed by tumor Complete Response have been observed in
the study.
Given the existing pre-clinical data and recent clinical data in Soft Tissue
Sarcoma patients (abstract ASCO 2017 number e14615 http://bit.ly/2rsNi2M)
showing the abiltity of NBTXR3 to trigger a specific adaptative immune pattern,
Nanobiotix will include an immulogical biomarkers analysis in this study.
Potential Value of NBTXR3 in this indication
In oncology, finding ways to impact overall survival rate and quality of life
with good safety is the ultimate goal. The preliminary findings seem to show
that NBTXR3 has the potential to do this.
The excellent safety profile demonstrated thus far in this elderly and frail
population, indicates that NBTXR3 would represent a valuable option to preserve
and improve Quality of Life compared to other treatments. This safety profile
also opens up opportunities for combinations with different types of treatment.
These encouraging results point towards a positive improvement of loco-regional
Control, impacting Overall Survival.
Next steps
Nanobiotix is filing a protocol amendment of this study to include 44 additional
patients in an expansion to demonstrate the efficacy of NBTXR3. Nanobiotix is
opening 12-15 additional sites in Europe to expand the development of this
indication. The company plans to expand this study in the US.
***
About NBTXR3 phase I/II trial in Head & Neck cancer
A significant proportion of head and neck carcinomas in the western world are
found in the oral cavity, and the oropharynx, the posterior continuation of the
oral cavity that connects with the nasopharynx (above) and laryngopharynx
(below).
These structures play a crucial role in swallowing, breathing and speaking.
Locally advanced oropharyngeal cancers can obstruct the airflow or infiltrate
muscles or nerves, significantly disrupting essential local functions. Response
in H&N cancer patients is related to: Age, stage, size, comorbidity,
localization of the tumor and infection by the human papilloma virus (presence
versus absence of HPV).
Local control of the tumor, when possible, is critical to preserve organ
function, quality of life and has a direct impact on the disease outcome
including Progression - Free Survival and (PFS) Overall Survival (OS).
Design
The target population for the Phase I/II trial are patients with locally
advanced squamous cell carcinoma of the oral cavity, tongue or oropharynx (Stage
T3 and T4), who are also classified as frail and elderly. They have a poorer
prognosis as compared to other Head and Neck cancer patients. In this population
tumor response and local control are usually very low compare to patients
eligible for combined treatment: radiotherapy plus cisplatin.
This study has targeted patients with bulky tumors, with significant invasion of
local tissues. In order to ensure the optimal treatment for every patient, the
design of the study has included two routes of injection of NBTXR3: intratumoral
injection and super selective intra-arterial injection.
Arm 1: Intra Tumoral (IT) injection, Dose escalation (5%, 10%, 15%, 22% of the
tumor volume). Number of patients could go up to 20 (3 to 6 patients per dose
level could be treated; 3 if no safety issues).
Arm 2: Intra Arterial (IA) injection, Dose escalation (5%, 10%, 15%, 22% of the
tumor volume). Number of patients could go up to 20 (3 to 6 patients per dose
level could be treated; 3 if no safety issues). Arm 2 has not been explored as
the IT injection in arm 1 has been shown to be feasible and successful.
Patients received 35 daily sessions (2GY per session) of radiotherapy starting
one day after the injection of NBTXR3 with a total of 70Gy (standard of care).
At 50Gy (71% of the total dose) tumor volume is evaluated to assess the
possibility of the patient to continue RTx (if tumor volume shrinkage is more
than 50%) and avoid further unnecessary radiation toxicity and salvage surgery.
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage
nanomedicine company pioneering novel approaches for the treatment of cancer.
The Company's first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy with a view to provide a new, more efficient treatment for
cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are
meant to treat potentially a wide variety of solid tumors including soft tissue
sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer,
glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers,
prostate cancer, and liver cancers (primary and metastases). Additionally, head
and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner,
PharmaEngine, are underway in the Asia Pacific region. The Company has filed in
August 2016 for market approval (CE Marking) in Europe for its lead product
NBTXR3.
The Company started in 2016 a new preclinical research program in Immuno-
oncology with its lead product NBTXR3, which could have the potential to bring a
new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN:
FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company
Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Contact
-------------------------------------------------------------------------------
Nanobiotix
-------------------------------------------------------------------------------
Sarah Gaubert Noël Kurdi
Director, Communications & Public Director, Investor Relations
Affairs +1 (646) 241-4400
+33 (0)1 40 26 07 55 noel.kurdi(at)nanobiotix.com /
sarah.gaubert(at)nanobiotix.com / investors(at)nanobiotix.com
contact(at)nanobiotix.com
--------------------------------------
Media relations
-------------------------------------------------------------------------------
France - Springbok Consultants United States -
Marina Rosoff RooneyPartners
+33 (0)6 71 58 00 34 Marion Janic
marina(at)springbok.fr +1 (212) 223-4017
mjanic(at)rooneyco.com
Disclaimer
This press release contains certain forward-looking statements concerning
Nanobiotix and its business. Such forward-looking statements are based on
assumptions that Nanobiotix considers to be reasonable. However, there can be no
assurance that the estimates contained in such forward-looking statements will
be verified, which estimates are subject to numerous risks including the risks
set forth in the update of the reference document of Nanobiotix filed with the
French Financial Markets Authority (Autorité des Marchés Financiers) under
number D.16-0732-A01 on December 27, 2016 (a copy of which is available on
www.nanobiotix.com) and to the development of economic conditions, financial
markets and the markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to risks not yet
known to Nanobiotix or not currently considered material by Nanobiotix. The
occurrence of all or part of such risks could cause actual results, financial
conditions, performance or achievements of Nanobiotix to be materially different
from such forward-looking statements.
This press release and the information that it contains do not constitute an
offer to sell or subscribe for, or a solicitation of an offer to purchase or
subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not
bear a CE mark and is not permitted to be placed on the market or put into
service until NBTXR3 has obtained a CE mark.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NANOBIOTIX via GlobeNewswire
Bereitgestellt von Benutzer: hugin
" alt="Cannabis Wheaton Provides Update on Private Placement and Related MattersDatum: 05.06.2017 - 18:00 Uhr
Sprache: Deutsch
News-ID 546320
Anzahl Zeichen: 15272
contact information:
Town:
Paris
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
NANOBIOTIX (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
